Ying Zhou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ying Zhou has a total of 167 co-authors. Here are the top co-authors by number of shared publications:
- Bang-Ce Ye
Laboratory of Biosystems and Microanalysis, State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology , Shanghai 200237
44 shared publications - Zhen-Ping Zou
Laboratory of Biosystems and Microanalysis, State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai 200237, China
11 shared publications Zhen-Ping Zou
8 shared publicationsBang-Ce Ye
7 shared publicationsTing-Ting Fang
Laboratory of Biosystems and Microanalysis, State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology , Shanghai 200237
4 shared publicationsBang‐Ce Ye
Lab of Biosystems and Microanalysis, State Key Laboratory of Bioreactor Engineering East China University of Science and Technology Shanghai China
3 shared publications
Latest Publications
- Open Access
- 10 November 2026
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 54 (21)
A dual biocontainment system specifically constraining the transfer and escape of the engineered plasmid in microbial communities
A variety of engineered genetic elements and circuits enable bacteria to sense environmental signals, process information, and execute programmed biological functions. However, the potential escape from such synthetic constructs into the natural environment poses biosafety risks and could disrupt ecological balance. To address this, we developed a dual biocontainment system designed to restrict the replication and expression of engineered plasmids exclusively within modified host (TEV protease and sgRNA-dCas9). This system employs TEV protease to remove ssrA degradation tags fused to the plasmid replication protein RepA, thereby enabling plasmid replication. Concurrently, a specific guide RNA (sgRNA) forms an inhibitory complex with dCas9 to prevent cleavage of the engineered plasmid by the I-OnuI endonuclease. Overall, dual biocontainment system provides a robust safety tool both in vitro and in vivo to restrict the transfer and escape of engineered plasmids (with an escape rate of 4.4 × 10−8 in vitro and 2.4 × 10−8 in vivo), giving an efficient platform for safely use of synthetic genetic elements.
- 10 November 2026
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 54 (21)
Open AccessA dual biocontainment system specifically constraining the transfer and escape of the engineered plasmid in microbial communities
A variety of engineered genetic elements and circuits enable bacteria to sense environmental signals, process information, and execute programmed biological functions. However, the potential escape from such synthetic constructs into the natural environment poses biosafety risks and could disrupt ecological balance. To address this, we developed a dual biocontainment system designed to restrict the replication and expression of engineered plasmids exclusively within modified host (TEV protease and sgRNA-dCas9). This system employs TEV protease to remove ssrA degradation tags fused to the plasmid replication protein RepA, thereby enabling plasmid replication. Concurrently, a specific guide RNA (sgRNA) forms an inhibitory complex with dCas9 to prevent cleavage of the engineered plasmid by the I-OnuI endonuclease. Overall, dual biocontainment system provides a robust safety tool both in vitro and in vivo to restrict the transfer and escape of engineered plasmids (with an escape rate of 4.4 × 10−8 in vitro and 2.4 × 10−8 in vivo), giving an efficient platform for safely use of synthetic genetic elements.
- Open Access
In situ-activated engineered bacteria release combined dual-therapeutic proteins for tumor immunotherapy
- 6 September 2026
- Published by American Chemical Society (ACS) in Journal of Agricultural and Food Chemistry
- Vol. 74 (36) , 28570-28582
Engineering a Transcription Activation Toolkit by Rewiring Prokaryotic Transcription Factors and Synthetic Yeast Promoters in Yarrowia lipolytica
Yarrowia lipolytica is a promising industrial host, yet its metabolic engineering potential remains limited by insufficient genetic tools. Here, we engineered a synthetic Transcription Activation Toolkit (TAT) based on LacI–VPRH, a chimeric protein fusing the prokaryotic DNA-binding domain LacI with the eukaryotic activation domain VPRH. Systematic optimization of LacO copy numbers and core promoter composition achieved up to 205-fold gene activation. The TAT platform was further expanded to construct bidirectional expression systems and enable multiplexed gene control. Applied to resveratrol biosynthesis via a “push-pull” strategy, CRISPR/Cas9-mediated integration of TAT-controlled synthetic promoters upregulated the shikimate pathway genes aroM10 and aroC alongside the rate-limiting enzyme ST1, achieving a shake-flask titer of 2.715 g/L─the highest reported to date. Additionally, an IPTG-inducible “turn-on” system (TAT-2.0) incorporating the antiLacI9 mutant was developed for small-molecule-responsive transcriptional control. Collectively, the modular TAT system provides a versatile strategy for precise metabolic pathway optimization in Y. lipolytica.
- 6 September 2026
- Published by American Chemical Society (ACS) in Journal of Agricultural and Food Chemistry
- Vol. 74 (36) , 28570-28582
Engineering a Transcription Activation Toolkit by Rewiring Prokaryotic Transcription Factors and Synthetic Yeast Promoters in Yarrowia lipolytica
Yarrowia lipolytica is a promising industrial host, yet its metabolic engineering potential remains limited by insufficient genetic tools. Here, we engineered a synthetic Transcription Activation Toolkit (TAT) based on LacI–VPRH, a chimeric protein fusing the prokaryotic DNA-binding domain LacI with the eukaryotic activation domain VPRH. Systematic optimization of LacO copy numbers and core promoter composition achieved up to 205-fold gene activation. The TAT platform was further expanded to construct bidirectional expression systems and enable multiplexed gene control. Applied to resveratrol biosynthesis via a “push-pull” strategy, CRISPR/Cas9-mediated integration of TAT-controlled synthetic promoters upregulated the shikimate pathway genes aroM10 and aroC alongside the rate-limiting enzyme ST1, achieving a shake-flask titer of 2.715 g/L─the highest reported to date. Additionally, an IPTG-inducible “turn-on” system (TAT-2.0) incorporating the antiLacI9 mutant was developed for small-molecule-responsive transcriptional control. Collectively, the modular TAT system provides a versatile strategy for precise metabolic pathway optimization in Y. lipolytica.
- 28 May 2026
- Published by American Chemical Society (ACS) in ACS Sensors
- Vol. 11 (6) , 4870-4879
Development of a Core−Shell-Encapsulated Biosensor for On-Site Detection of Trace Chlorpyrifos
Chlorpyrifos, a broad-spectrum organophosphorus pesticide, accumulates persistently in the environment and food chain, posing significant risks to ecosystems and human health. Whole-cell biosensors offer a promising alternative for on-site pesticide detection. However, their practical application is hindered by insufficient sensitivity for trace residues and biosafety concerns. Here, we developed a core−shell hydrogel-encapsulated whole-cell biosensor for the sensitive and safe detection of trace-level chlorpyrifos. A metabolic module was integrated into the basic ChpR-PchpA genetic circuit to enhance sensitivity through signal amplification. This was realized through an enzymatic transformation of weakly activating substrates into derivatives with strong activating potential. This approach amplified the output signal and lowered the detection limit by 32-fold to 0.75 nM, meeting the stringent regulatory thresholds for chlorpyrifos residues. Furthermore, a physical containment approach based on core−shell hydrogel microbeads effectively prevented bacterial escape while maintaining high cell viability and sensing performance. The encapsulated biosensor remained active over 30 days of storage and showed reliable performance in real vegetable, water, and soil samples with satisfactory recoveries. This work provides a robust, field-deployable, and environmentally safe platform for monitoring trace chlorpyrifos residues in complex environmental matrices.
- 28 May 2026
- Published by American Chemical Society (ACS) in ACS Sensors
- Vol. 11 (6) , 4870-4879
Development of a Core−Shell-Encapsulated Biosensor for On-Site Detection of Trace Chlorpyrifos
Chlorpyrifos, a broad-spectrum organophosphorus pesticide, accumulates persistently in the environment and food chain, posing significant risks to ecosystems and human health. Whole-cell biosensors offer a promising alternative for on-site pesticide detection. However, their practical application is hindered by insufficient sensitivity for trace residues and biosafety concerns. Here, we developed a core−shell hydrogel-encapsulated whole-cell biosensor for the sensitive and safe detection of trace-level chlorpyrifos. A metabolic module was integrated into the basic ChpR-PchpA genetic circuit to enhance sensitivity through signal amplification. This was realized through an enzymatic transformation of weakly activating substrates into derivatives with strong activating potential. This approach amplified the output signal and lowered the detection limit by 32-fold to 0.75 nM, meeting the stringent regulatory thresholds for chlorpyrifos residues. Furthermore, a physical containment approach based on core−shell hydrogel microbeads effectively prevented bacterial escape while maintaining high cell viability and sensing performance. The encapsulated biosensor remained active over 30 days of storage and showed reliable performance in real vegetable, water, and soil samples with satisfactory recoveries. This work provides a robust, field-deployable, and environmentally safe platform for monitoring trace chlorpyrifos residues in complex environmental matrices.
- 11 March 2026
- Published by American Chemical Society (ACS) in ACS Synthetic Biology
- Vol. 15 (4) , 1412-1425
Metabolic Engineering of Commensal Bacteria for Producing 5-Hydroxyindoleacetic Acid as a Therapeutic Strategy for Colitis
Numerous studies have demonstrated a strong association between gut microbiota dysbiosis and the progression of colitis, potentially mediated by disruptions in microbial tryptophan metabolism. Targeting commensal bacterial tryptophan metabolism may offer a promising therapeutic strategy. However, a broader spectrum of active substances is necessary to diversify engineered probiotics and enhance the efficacy and precision of treatments. In this study, using a dextran sulfate sodium (DSS)-induced murine colitis model for active substance screening, we observed a significant alteration of the gut microbiota structure concurrent with a pronounced decrease in the level of the microbial-derived tryptophan metabolite, 5-hydroxyindoleacetic acid (5-HIAA). Exogenous supplementation with 5-HIAA restored intestinal epithelial barrier integrity and alleviated colitis symptoms. Mechanistically, 5-HIAA activates the aryl hydrocarbon receptor (AhR), leading to enhanced transcription of IL-10 and subsequent modulation of the NF-κB p65/MLCK/pMLC signaling pathway in intestinal epithelial cells. This cascade promotes increased expression of tight junction proteins, thereby improving intestinal barrier function and attenuating colitis. Furthermore, we engineered a facultative anaerobic commensal bacterium capable of delivering 5-HIAA directly to the gut and evaluated its efficacy in a mouse model of colitis. Our findings indicate that targeted modulation of the key microbial metabolite 5-HIAA effectively suppresses the onset and progression of colitis. The use of engineered bacteria for site-specific 5-HIAA delivery represents a novel and promising therapeutic approach for inflammatory bowel disease (IBD).
- 11 March 2026
- Published by American Chemical Society (ACS) in ACS Synthetic Biology
- Vol. 15 (4) , 1412-1425
Metabolic Engineering of Commensal Bacteria for Producing 5-Hydroxyindoleacetic Acid as a Therapeutic Strategy for Colitis
Numerous studies have demonstrated a strong association between gut microbiota dysbiosis and the progression of colitis, potentially mediated by disruptions in microbial tryptophan metabolism. Targeting commensal bacterial tryptophan metabolism may offer a promising therapeutic strategy. However, a broader spectrum of active substances is necessary to diversify engineered probiotics and enhance the efficacy and precision of treatments. In this study, using a dextran sulfate sodium (DSS)-induced murine colitis model for active substance screening, we observed a significant alteration of the gut microbiota structure concurrent with a pronounced decrease in the level of the microbial-derived tryptophan metabolite, 5-hydroxyindoleacetic acid (5-HIAA). Exogenous supplementation with 5-HIAA restored intestinal epithelial barrier integrity and alleviated colitis symptoms. Mechanistically, 5-HIAA activates the aryl hydrocarbon receptor (AhR), leading to enhanced transcription of IL-10 and subsequent modulation of the NF-κB p65/MLCK/pMLC signaling pathway in intestinal epithelial cells. This cascade promotes increased expression of tight junction proteins, thereby improving intestinal barrier function and attenuating colitis. Furthermore, we engineered a facultative anaerobic commensal bacterium capable of delivering 5-HIAA directly to the gut and evaluated its efficacy in a mouse model of colitis. Our findings indicate that targeted modulation of the key microbial metabolite 5-HIAA effectively suppresses the onset and progression of colitis. The use of engineered bacteria for site-specific 5-HIAA delivery represents a novel and promising therapeutic approach for inflammatory bowel disease (IBD).
- Open Access
- 13 February 2026
- Published by Springer Nature in Research Square
Programming Microbe-Computer Interaction for Customized Life-Nonlife and Cross-Life Communication
The extension of human-computer interaction (HCI) paradigm to non-intelligent microbe-computer interaction (MCI) is attractive for building generalized life-nonlife communication. Main challenges lie in how to construct biohybrid interface within individual MCI unit and program communication among different units. Here, we designed opto-interfaced MCI unit composed of engineered microbes and computer terminals, for enabling quantifiable transduction between microbial signals and digital signals. These units were able to serve as life-centric biohybrid sensors, actuators and transceivers. Based on these units, we established programmable cross-life communication architectures capable of unicast, multicast, and logic-gate-driven communication with dynamic control. The architectures were validated in in multiple scenarios, including the biomedical monitoring-triggered therapeutic intervention at tumor, epidermal and intestinal scenarios, and the environmental unmanned monitoring of water contaminants. In summary, we provide a scalable strategy for building customized life-nonlife and cross-life communication, which is expected to complement living biosystems into the internet of things (IoT).
- 13 February 2026
- Published by Springer Nature in Research Square
Open AccessProgramming Microbe-Computer Interaction for Customized Life-Nonlife and Cross-Life Communication
The extension of human-computer interaction (HCI) paradigm to non-intelligent microbe-computer interaction (MCI) is attractive for building generalized life-nonlife communication. Main challenges lie in how to construct biohybrid interface within individual MCI unit and program communication among different units. Here, we designed opto-interfaced MCI unit composed of engineered microbes and computer terminals, for enabling quantifiable transduction between microbial signals and digital signals. These units were able to serve as life-centric biohybrid sensors, actuators and transceivers. Based on these units, we established programmable cross-life communication architectures capable of unicast, multicast, and logic-gate-driven communication with dynamic control. The architectures were validated in in multiple scenarios, including the biomedical monitoring-triggered therapeutic intervention at tumor, epidermal and intestinal scenarios, and the environmental unmanned monitoring of water contaminants. In summary, we provide a scalable strategy for building customized life-nonlife and cross-life communication, which is expected to complement living biosystems into the internet of things (IoT).
- 8 January 2026
- Published by Oxford University Press (OUP) in Journal of Animal Science
- Vol. 104
Dietary triple-strain Bacillus -based probiotic improves growth performance by modulating intestinal barrier function and gut microbiota in weaned pigs
This study aimed to investigate the effects of dietary supplementation with a triple-strain Bacillus-based probiotic (BP) on growth performance, intestinal barrier function, and gut microbial composition in weaned pigs. A total of 160 piglets (initial body weight, 8.0 ± 0.25 kg; 28 d of age) were randomly assigned to four treatments: a basal diet (CON) or the basal diet supplemented with 100 mg/kg (BP100, 4 × 107 colony-forming unit [CFU]/kg feed), 200 mg/kg (BP200, 8 × 107 CFU/kg feed), and 400 mg/kg (BP400, 1.6 × 108 CFU/kg feed) a triple-strain Bacillus probiotic containing Bacillus subtilis PB6, Bacillus subtilis FXA, and Bacillus licheniformis G3. Each treatment included 8 replicate pens with 5 pigs per pen. Over the 35-d feeding period (Phase 1: d 0–14; Phase 2: d 15–35), increasing dietary BP supplementation linearly improved average daily gain and feed efficiency (P < 0.05) and reduced the diarrhea index by up to 49.3% relative to the CON (P < 0.05), whereas average daily feed intake was unaffected. Apparent nutrient digestibility increased, whereas organic matter, gross energy, and nitrogen excretion decreased linearly with increasing BP supplementation (P < 0.10). Dietary BP supplementation linearly increased villus height, villus height-to-crypt depth ratio, goblet cell numbers, and tight junction protein expression, while reducing crypt depth in the small intestine (P < 0.05). In addition, increasing dietary BP supplementation linearly increased colonic Lactobacillus abundance and the concentrations of acetic acid, propionic acid, butyric acid, and total short-chain fatty acids, with the greatest values observed in the BP400 (P < 0.05). In conclusion, dietary BP supplementation improved growth performance in weaned pigs by enhancing intestinal morphological development and barrier integrity, increasing nutrient digestibility, and modulating the composition and metabolic activity of the gut microbiota. These findings highlight the potential of BP as an effective functional feed additive to mitigate weaning stress through improvements in intestinal barrier function and modulation of gut microbiota.
- 8 January 2026
- Published by Oxford University Press (OUP) in Journal of Animal Science
- Vol. 104
Dietary triple-strain Bacillus -based probiotic improves growth performance by modulating intestinal barrier function and gut microbiota in weaned pigs
This study aimed to investigate the effects of dietary supplementation with a triple-strain Bacillus-based probiotic (BP) on growth performance, intestinal barrier function, and gut microbial composition in weaned pigs. A total of 160 piglets (initial body weight, 8.0 ± 0.25 kg; 28 d of age) were randomly assigned to four treatments: a basal diet (CON) or the basal diet supplemented with 100 mg/kg (BP100, 4 × 107 colony-forming unit [CFU]/kg feed), 200 mg/kg (BP200, 8 × 107 CFU/kg feed), and 400 mg/kg (BP400, 1.6 × 108 CFU/kg feed) a triple-strain Bacillus probiotic containing Bacillus subtilis PB6, Bacillus subtilis FXA, and Bacillus licheniformis G3. Each treatment included 8 replicate pens with 5 pigs per pen. Over the 35-d feeding period (Phase 1: d 0–14; Phase 2: d 15–35), increasing dietary BP supplementation linearly improved average daily gain and feed efficiency (P < 0.05) and reduced the diarrhea index by up to 49.3% relative to the CON (P < 0.05), whereas average daily feed intake was unaffected. Apparent nutrient digestibility increased, whereas organic matter, gross energy, and nitrogen excretion decreased linearly with increasing BP supplementation (P < 0.10). Dietary BP supplementation linearly increased villus height, villus height-to-crypt depth ratio, goblet cell numbers, and tight junction protein expression, while reducing crypt depth in the small intestine (P < 0.05). In addition, increasing dietary BP supplementation linearly increased colonic Lactobacillus abundance and the concentrations of acetic acid, propionic acid, butyric acid, and total short-chain fatty acids, with the greatest values observed in the BP400 (P < 0.05). In conclusion, dietary BP supplementation improved growth performance in weaned pigs by enhancing intestinal morphological development and barrier integrity, increasing nutrient digestibility, and modulating the composition and metabolic activity of the gut microbiota. These findings highlight the potential of BP as an effective functional feed additive to mitigate weaning stress through improvements in intestinal barrier function and modulation of gut microbiota.
- Open Access
- 1 December 2025
- Published by KEAI Publishing in Synthetic and Systems Biotechnology
- Vol. 10 (4) , 1172-1179
Engineering Yarrowia lipolytica for high-level β-elemene production via combinatorial metabolic strategies
β-Elemene, a pharmacologically active sesquiterpene derived from the traditional Chinese medicinal herb Curcuma wenyujin, exhibits broad-spectrum anti-tumor and anti-inflammatory activities. Currently, its commercial production relies heavily on plant extraction, a process associated with high costs and environmental burdens, limiting industrial scalability. To address these challenges, we developed a metabolically engineered Yarrowia lipolytica strain as an efficient microbial cell factory for de novo Germacrene A biosynthesis, the direct precursor of β-elemene. Through combinatorial optimization strategies—including (1) mevalonate (MVA) pathway enhancement, (2) copy number amplification of germacrene A synthase (GAS), (3) β-oxidation pathway reinforcement, and (4) introduction of the isopentenyl utilization pathway (IUP)—we significantly improved β-elemene production. The engineered strain achieved a titer of 3.08 ± 0.05 g/L in shake-flask cultures, with a yield of 51.27 ± 0.75 mg/g glucose, representing a 3.5-fold increase over the parental strain. Our work highlights the potential of Y. lipolytica as a sustainable and scalable platform for high-value sesquiterpene production, offering a viable alternative to plant-derived extraction.
- 1 December 2025
- Published by KEAI Publishing in Synthetic and Systems Biotechnology
- Vol. 10 (4) , 1172-1179
Open AccessEngineering Yarrowia lipolytica for high-level β-elemene production via combinatorial metabolic strategies
β-Elemene, a pharmacologically active sesquiterpene derived from the traditional Chinese medicinal herb Curcuma wenyujin, exhibits broad-spectrum anti-tumor and anti-inflammatory activities. Currently, its commercial production relies heavily on plant extraction, a process associated with high costs and environmental burdens, limiting industrial scalability. To address these challenges, we developed a metabolically engineered Yarrowia lipolytica strain as an efficient microbial cell factory for de novo Germacrene A biosynthesis, the direct precursor of β-elemene. Through combinatorial optimization strategies—including (1) mevalonate (MVA) pathway enhancement, (2) copy number amplification of germacrene A synthase (GAS), (3) β-oxidation pathway reinforcement, and (4) introduction of the isopentenyl utilization pathway (IUP)—we significantly improved β-elemene production. The engineered strain achieved a titer of 3.08 ± 0.05 g/L in shake-flask cultures, with a yield of 51.27 ± 0.75 mg/g glucose, representing a 3.5-fold increase over the parental strain. Our work highlights the potential of Y. lipolytica as a sustainable and scalable platform for high-value sesquiterpene production, offering a viable alternative to plant-derived extraction.
- 19 November 2025
- Published by American Chemical Society (ACS) in ACS Sensors
- Vol. 10 (11) , 8424-8434
Magnetic Hydrogel: Enhanced Bacterial Biosensor for Speedy Gut Disease Detection
Bacterial biosensors represent a promising avenue for detecting gastrointestinal disease biomarkers; however, their direct oral delivery is limited by challenges such as bioavailability, safety, and interactions with the complex gut microbiota. To address these issues, we developed MagGel-BS, a Magnetic hydroGel-encapsulated Bacterial bioSensor platform. This hybrid system combines biocompatible alginate hydrogel to encapsulate both magnetic particles and bacterial biosensors, facilitating precise detection of disease biomarkers. The hydrogel significantly enhances stability, improving bacterial viability in gastric fluid by 10-fold. Utilizing heme-responsive bacteria, MagGel-BS was able to detect gastrointestinal bleeding in mice within only 20 min, a significant improvement compared to unencapsulated biosensors, which took several hours. Importantly, MagGel-BS showed no immune responses or adverse effects in vivo. In summary, this platform provides a rapid, noninvasive approach for gastrointestinal biomarker detection, demonstrating considerable potential for advancing bacterial-based diagnostics and therapeutics applications.
- 19 November 2025
- Published by American Chemical Society (ACS) in ACS Sensors
- Vol. 10 (11) , 8424-8434
Magnetic Hydrogel: Enhanced Bacterial Biosensor for Speedy Gut Disease Detection
Bacterial biosensors represent a promising avenue for detecting gastrointestinal disease biomarkers; however, their direct oral delivery is limited by challenges such as bioavailability, safety, and interactions with the complex gut microbiota. To address these issues, we developed MagGel-BS, a Magnetic hydroGel-encapsulated Bacterial bioSensor platform. This hybrid system combines biocompatible alginate hydrogel to encapsulate both magnetic particles and bacterial biosensors, facilitating precise detection of disease biomarkers. The hydrogel significantly enhances stability, improving bacterial viability in gastric fluid by 10-fold. Utilizing heme-responsive bacteria, MagGel-BS was able to detect gastrointestinal bleeding in mice within only 20 min, a significant improvement compared to unencapsulated biosensors, which took several hours. Importantly, MagGel-BS showed no immune responses or adverse effects in vivo. In summary, this platform provides a rapid, noninvasive approach for gastrointestinal biomarker detection, demonstrating considerable potential for advancing bacterial-based diagnostics and therapeutics applications.
- 15 October 2025
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
- Vol. 13 (45) , 14535-14555
Engineered microbial sensors: providing a new paradigm for disease detection
This review provides a comprehensive overview of the design, recent advancements, micro- and macro-encapsulation strategies, and clinical applications of engineered microbial sensors in disease diagnostics.
- 15 October 2025
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
- Vol. 13 (45) , 14535-14555
Engineered microbial sensors: providing a new paradigm for disease detection
This review provides a comprehensive overview of the design, recent advancements, micro- and macro-encapsulation strategies, and clinical applications of engineered microbial sensors in disease diagnostics.